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ABSTRACT:	Clavulanate	is	used	as	an	effective	drug	in	combination	with	β-lactam	antibiotics	 to	 treat	 infec-tions	 of	 some	antibiotic	 resistant	 bacteria.	 Here,	we	perform	 combined	 quantum	mechanics	 /	molecular	mechanics	simulations	of	several	covalent	complexes	of	 clavulanate	 with	 class	 A	 β-lactamases	 KPC-2	 and	TEM-1.	Simulations	of	the	deacylation	reactions	iden-tify	the	decarboxylated	trans-enamine	complex	as	re-sponsible	for	inhibition.	Further,	the	obtained	free	en-ergy	 barriers	 discriminate	 clinically	 relevant	 inhibi-tion	(TEM-1)	from	less	effective	inhibition	(KPC-2).	
Antibiotic	 resistance	 is	 one	 of	 the	 greatest	 global	threats	to	human	health.1	Resistance	to	almost	every	class	 of	 clinically	 approved	 antibiotic	 has	 been	 ob-served.2,3	The	increase	and	global	spread	of	bacterial	antimicrobial	resistance	limits	treatment	options	and	affects	many	aspects	of	medicine,	from	cancer	to	organ	transplants.		In	the	worst	case,	no	effective	treatment	may	 be	 available	 for	 bacterial	 infections.4,5	 β-lactam	antibiotics	are	a	mainstay	of	modern	medicine	but	suf-fer	from	increasing	resistance	in	bacteria.	β-lactamase	enzymes	are	the	key	source	of	resistance	for	many	hu-man	 pathogens	 (particularly	 Gram-negative	 bacte-ria).2	 Inhibitors	 of	 these	 enzymes	 are	 clinically	 im-portant:	given	in	conjunction	with	β-lactam	antibiot-ics,	they	can	restore	the	effectiveness	of	the	antibiotic.	Only	 five	 β-lactamase	 inhibitors	 are	 currently	 clini-cally	 approved:	 clavulanate	 (CLA),	 sulbactam	 (SUL),	tazobactam	 (TAZ)	 and	 the	 non-b-lactam	 agents	 avi-bactam	(AVI)	and	vaborbactam	(VAB);	and	resistance	to	them	is	also	increasing.6–11	Discovery	and	develop-ment	of	new	compounds	with	 this	 type	of	biological	activity	 is	 necessary	 to	 combat	 antibiotic	 resistance	and	to	recover	the	usefulness	of	β-lactam	antibiotics.12	
β-lactam	antibiotics	are	covalent	inhibitors	of	bacte-rial	DD-trans-peptidases.12	β-lactamases	inactivate	β-lactams	 by	 hydrolyzing	 the	amide	bond	 of	 the	 four-membered	 β-lactam	 ring,	 in	 serine	 β-lactamases	(SBLs)	via	a	transient	covalent	acylenzyme	intermedi-ate.	 β-lactamase	 inhibitors	 also	 bind	 covalently	 to	SBLs12	but	 the	 inhibitor	 remains	 covalently	attached	to	the	active	site	serine,	preventing	the	enzyme	from	turning	over.13–15	Crucially,	to	be	effective,	the	rate	of	breaking	this	bond	must	be	slow.	Research	on	covalent	drugs	has	increased	in	recent	years	due	e.g.	to	the	pos-sibility	of	prolonged	residence	times.	Successful	exam-ples	include	covalent	inhibitors	of	kinases.16,17	In-silico	methods,	such	as	docking	and	quantitative	structure-activity	 relationship	 models,	 can	 play	 an	 important	role	 in	 designing	 and	 developing	 covalent	 drugs.	 To	understand	reactivity	and	specificity	of	covalent	bind-ers	 to	protein	 targets,	and	 related	drug	 resistance18,	combined	quantum	mechanics/molecular	mechanics	(QM/MM)	 methods	 are	 a	 highly	 promising	 ap-proach.15,19–21	Acylation	of	SBLs	by	β-lactamase	inhibitors	is	likely	to	occur	with	the	same	mechanism	as	for	β-lactam	an-tibiotics	such	as	benzyl-penicillin	(Figs.	S1).22	In	class	A	b-lactamases,	 the	most	widespread	 SBLs,	 deacyla-tion	consists	of	proton	abstraction	from	a	conserved	water	molecule	 (deacylating	water,	 DW)	 by	 Glu166,	and	nucleophilic	attack	by	DW	on	the	ester	carbon	of	the	acyl–enzyme	complex	(AEC)	with	subsequent	re-lease	of	the	inactivated	antibiotic.23	Carbapenems	that	inhibit	β-lactamases	show	a	stable	AEC,19	thus	the	rate	of	deacylation	is	central	to	activity.	In	the	case	of	inhib-itors,	 after	 the	AEC	 is	 formed	and	depending	on	the	properties	of	the	β-lactamase	and	inhibitor,	the	reac-tion	will	proceed	 to	deacylation	 (Fig.	 S1-S3)	or	 irre-versible	inactivation6	(i.e.	formation	of	one	of	several	proposed	 protein-ligand	 covalent	 complexes	 or	
 adducts).	Then,	opening	of	the	five-membered	ring	of	the	β-lactam	inhibitor	(CLA,	TAZ	or	SUL)	AEC	leads	to	formation	of	a	transient	imine	intermediate,	which	re-arranges	to	form	an	enamine	species,	in	either	a	trans	or	a	cis	conformation.6,24	Ultimately,	a	stable	covalent	complex	is	reached	and	a	slow	hydrolysis	or	deacyla-tion	rate	is	observed	(Fig	S5).	Irreversible	inhibition	is	possible	when	a	trans-enamine	decarboxylated	com-plex	 (TEDC)	 for	 CLA,	 or	 a	 trans-enamine	 complex	(TEC)	in	the	case	of	SUL	and	TAZ,	is	formed.	An	alde-hyde	complex	(ADEC)	can	also	be	reached	by	consec-utive	reactions	of	the	cis-enamine6,24	(Fig.	S3-S4).	Spe-cifically,	TEDC	and	TEC	have	been	trapped	and	charac-terized	through	X-ray	and	Raman	spectroscopy	exper-iments	 in	 complex	with	 SHV-1	 β-lactamase	 and	mu-tants	thereof.25–29		Among	the	Class	A	β-lactamases,	TEM-1	and	KPC-2	are	well	studied	and	clinically	important	enzymes	that	in	addition	 to	differences	 in	 specificity	 towards	 sub-strates	are	distinguished	by	differing	 susceptibilities	to	inhibition	by	CLA.	Both	enzymes	hydrolyze	the	in-hibitor,	but	at	different	rates	(kcat	in	Table	1).	This	fea-ture	 translates	 into	 KPC-2	 resistance	 to	 CLA	 action.	TEM-1	and	KPC-2	also	show	distinct	inactivation	rates	as	 measured	 by	 their	 respective	 kinact	 values	 (Table	1).6,7	While,	in	general,	the	kinact/Ki	ratio	is	the	most	ef-fective	measure	 of	 irreversible	 inhibition30	 as	 inclu-sion	of	Ki	values	accounts	for	effects	on	both	acylation	and	deacylation	rates,	in	this	instance	kinact	alone	can	effectively	 report	 irreversible	 inhibition	 by	 CLA	 of	TEM-1	 and	 KPC-2	 as	 deacylation	 is	 the	 more	 im-portant	and	limiting	step	in	inhibition.	In	this	case	CLA	is	a	substantially	less	effective	inhibitor	of	KPC-2	than	TEM-1,	making	infections	by	KPC-2	producing	bacte-ria	insusceptible	to	treatment	by	β-lactam/CLA	com-binations.6,7		A	QM/MM	protocol,	modelling	the	first	step	of	deac-ylation	 in	 Class	 A	 β-lactamases,	 was	 developed	 by	Chudyk	et	al.,	and	shown	to	be	an	effective	computa-tional	‘assay’	for	carbapenemase	activity	of	class	A	β-lactamases.19	With	 SCC-DFTB31	 as	 QM	 method,	 en-zymes	 inhibited	by	carbapenems	showed	barriers	of	17-18	kcal/mol	for	the	first	deacylation	step,	whereas	non-inhibited	enzymes	 showed	 a	 significantly	 lower	barriers	 (≤	 10	 kcal/mol).	 The	 simulations	 thus	 cor-rectly	discriminated	between	β-lactamases	with	 car-bapenemase	activity	and	those	without.	Here,	we	ap-ply	a	similar	simulation	protocol	to	study	deacylation	of	covalent	β-lactamase-inhibitor	complexes.	We	cal-culate	activation	free	energies	for	deacylation	(Δ‡Gcalc),	for	the	different	covalent	complexes	TEDC,	ADEC	and	AEC	 (used	as	a	 control	 calculation	 for	 the	 screening	method)	 formed	 between	 CLA	 and	 Class	 A	 β-lac-tamases	 TEM-1	and	KPC-2	 (Fig	 S4).	 Our	 aim	was	 to	identify	the	complexes	responsible	for	irreversible	in-hibition	and	 to	 illustrate	that	 the	QM/MM	screening	
methodology	can	be	extended	to	predict	inhibition	of	Class	A	β-lactamases	by	other	molecules	of	interest.	Class	 A	 β-lactamase	 crystal	 structures	 of	 TEDC,	ADEC	 and	 AEC	 complexes	 were	 used	 to	 build	 these	into	TEM-1	(PDB:	1BTL)	and	KPC-2	(PDB:	2OV5),	re-taining	 the	 structurally	 conserved	 deacylating	water	(DW).	The	models	were	 structurally	 refined	and	 the	adduct	prepared	for	QM/MM	simulation	using	a	MM	relaxation	protocol	(details	in	ESI;	adduct	parameters	at	 DOI:	 10.6084/m9.figshare.6301976).	 Thereafter,	50	 ps	 of	 QM/MM	 production	 MD	 was	 performed	without	restraints	prior	to	each	reaction	simulation,	to	generate	independent	starting	points.	The	DW,	Ser70-adduct	 and	 sidechain	 of	 Glu166,	 from	 its	 Cβ	 atom,	were	selected	as	the	quantum	mechanical	(QM)	region	(Figure	 1),	 which	 was	 described	 with	 SCC-DFTB,31	while	 the	 rest	 of	 the	 system	 was	 treated	 with	 the	ff14SB32	 MM	 force	 field.	 (see	 ESI	 for	 details).	 End	points	 of	 this	 equilibration	 were	 checked	 for	geometrical	 consistency	 for	 the	deacylation	 reaction	by	examining	the	key	catalytic	distances.	Reaction	co-ordinates	were	defined	as	previously19,23	(Figure	1).	
	
Figure	1.	Reaction	Coordinates	used	for	umbrella	sam-pling	MD	simulations	of	the	reactions.	QM	atoms	are	de-picted	as	hyperballs	with	NGLview.33	Complete	2D-energy	surfaces	were	then	obtained	by	QM/MM	 Umbrella	 Sampling	 (US)	 simulations	 along	the	 two	 defined	 reaction	 coordinates	 and	 using	 the	weighted-histogram	analysis	method	(WHAM;	details	in	ESI,	see	Figure	2,	Figures	S5-S22).	The	minimum	free	 energy	 path	 (MEP)	 on	 the	 surfaces	 was	 deter-mined	using	 the	Minimum	Energy	Pathway	Analysis	for	energy	landscapes	(MEPSA)	software.34	The	high-est	point	along	 the	MEP	was	 taken	as	 the	 transition	state	energy	to	obtain	Δ‡Gcalc.	Three	series	of	US	simu-lations,	with	different	starting	points	as	taken	from	the	unbiased	 QM/MM	MD	 runs	 were	 performed	 to	 test	convergence	of	Δ‡Gcalc.	
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 	Summarized	Δ‡Gcalc	and	relative	free	energy	differ-ences	ΔΔ‡G	(Δ‡G	KPC-2–Δ‡G	TEM-1)	values	for	the	differ-ent	enzyme	CLA-adducts	are	reported	in	Table	1.	The	calculated	deacylation	rates	for	the	AEC	and	ADEC	for	KPC-2	and	TEM-1	are	equal	 for	 these	adducts	 (ΔΔ‡G	values	 are	 less	 than	 the	 cumulative	 standard	 devia-tion)	and	are	of	the	same	order	of	magnitude	as	those	reported	 by	 Chudyk	 et	 al.	 19	 for	 deacylation	 of	 car-bapenem	AECs	by	carbapenem-hydrolyzing	class	A	b-lactamases.21	This	suggests	that	neither	the	AEC	nor	ADEC	 complex	 is	 responsible	 for	 irreversible	 inhibi-tion	(Table	1).7,35	In	contrast,	the	Δ‡Gcalc	values	for	the	TEDCs	in	KPC-2	and	TEM-1,	differ	substantially	from	those	 for	 the	 AEC	 or	 ADEC,	 identifying	 a	 markedly	higher	barrier	for	deacylation	and	strongly	supporting	the	contention	that	the	TEDC	is	the	covalent	complex	responsible	 for	 irreversible	 inhibition.6,7,24	Moreover,	these	values	agree	well	with	those	derived	 from	 the	respective	experimental	inactivation	constants	(kinact,	the	parameter	primarily	related	to	the	loss	of	enzyme	activity).7,35		Importantly,	our	computational	approach	also	differentiates	the	two	enzymes	(ΔΔ‡G	value	–5.1	kcal/mol);	distinguishing	efficient	inhibition	of	TEM-1	 	 from	 less	 effective	 inhibition	 of	 KPC-2	 and	 so	
replicating	what	 is	 observed	 both	 in	 in	 vitro	 experi-ments	and	in	the	clinic.		
	
Figure	2.	Free	Energy	Surface	for	the	first	step	of	deacyl-ation	of	TEDC	in	KPC-2.	R	=	reactants	(KPC-2,	TEDC	and	DW),	TS	=	“Transition	State”,	TI	=	Tetrahedral	Intermedi-ate	of	the	first	step	of	deacylation.	White	dots	represent	the	MEP	of	the	reaction.		
Table	1.	Experimental	(Δ‡Gexp)	and	calculated	free	energies	of	activation	(Δ‡Gcalc)	for	the	first	step	of	deacylation	of	TEDC,	ADEC	and	AEC;	and	kinetics	parameters.	Δ‡Gcalc	barriers	are	the	average	from	three	simulations	with	standard	deviations.	
β-lactamase		 kinact	(s–1)	 Δ‡Gexp	(kcal/mol)	 kcat	(s–1)	 Δ‡Gexp	(kcal/mol)	 Δ‡Gcalc	(kcal/mol)	TEDC	 ADEC	 AEC	KPC-2	 0.0277	 19.7	 1836	 15.8	 18.7	(0.6)	 7.5	(0.4)	 8.4	(1.6)	TEM-1	 0.001735	 21.3	 0.2135	 18.5	 23.8	(1.2)	 7.4	(0.2)	 7.3	(0.9)	ΔΔ‡G	 	 –1.6	 	 –2.6	 –5.1	 –0.1	 1.1	
1 The	KPC-2	TEDC	acyl-enzyme	simulations	 indicate	slightly	shorter	hydrogen	bonds	with	the	acyl	oxygen	(donated	by	the	Ser70	and	Thr/Ala237	amides)	than	in	TEM-1	(2.12±0.20	Å	and	1.86±0.12	Å	vs.	2.29±0.24	Å	and	1.93±0.13	Å,	respectively),	which	may	be	related	to	the	distinct	conformation	of	the	protein	backbone	likely	 imposed	 by	 the	 Cys69-Cys238	 disulfide	 bond	(present	in	KPC-2	only).37	Apart	from	this	small	differ-ence	 in	 the	 acyl-enzyme	 complexes,	 simulations	 do	not	indicate	a	clear	effect	that	explains	the	difference	in	barrier	between	TEM-1	and	KPC-2	 (Figures	S23-
S26).	This	is	consistent	with	what	we	have	observed	previously	for	carbapenem	breakdown	in	class	A	beta-lactamases19:	multiple	subtle	effects	are	likely	to	be	in	play.	 The	 first-principles	 QM/MM	 reaction	 simula-tions	 performed	 here	 are	 able	 to	 incorporate	 these	subtle	effects.	Indeed,	detailed	investigation	of	reactiv-ity	will	likely	be	necessary	to	understand	the	origins	of	differences	 in	the	 inhibition	efficiency	of	serine	β-lactamases	with	covalent	b-lactam	inhibitors.	
In	 conclusion,	 QM/MM	 reaction	 simulations	 were	used	to	calculate	Δ‡Gcalc	for	the	first	deacylation	step	in	β-lactamases	 with	 three	 different	 CLA	 adducts;	 the	acyl,	aldehyde	and	decarboxylated	trans-enamine	en-zyme	complexes.	The	higher	activation	 free	energies	for	deacylation	of	the	latter	(TEDC)	adduct	lead	us	to	conclude	that	this	is	the	complex	responsible	for	irre-versible	 inhibition	 of	 both	 enzymes.	 We	 thus	 show	that	the	QM/MM	screening	protocol	is	reliable	in	dis-criminating	 the	 inhibitory	 activity	 of	 different	 cova-lent	complexes	in	class	A	β-lactamases.	Furthermore,	the	computational	screening	method	is	able	to	differ-entiate	enzymes	for	which	CLA	is	an	effective	inhibitor	(TEM-1)	from	those	for	which	it	is	not	(KPC-2).	Taken	together	 with	 our	 previous	 results	 on	 carbapenem	deacylation,19	 these	data	 show	 that	QM/MM	simula-tion	 protocols	 assessing	 likelihood	 of	 deacylation	 in	class	A	β-lactamase	AECs	are	applicable	to	chemically	distinct	 acylated	 moieties	 in	 different	 enzymes.	QM/MM	screening	of	inhibitory	activity	against	class	A	 β-lactamases	 could	 thus	 help	 design	 better	 β-
 lactamase	 inhibitors	 as	 well	 as	 β-lactam	 antibotics,	with	 the	 possibility	 of	 expanding	 the	 procedure	 to	other	 serine	 β-lactamases	 (and	 other	 serine	 hydro-lases).	
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